Abstract
Purpose
This study aimed to compare the diagnostic accuracy of [18F]fluorodeoxyglucose (FDG) positron emission tomography (PET)/ magnetic resonance imaging (MRI) and [18F]FDG PET/ computed tomography (CT) in tumor–node–metastasis staging of non-small-cell lung cancer.
Methods
The study followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses for Diagnostic Test Accuracy (PRISMA-DTA) guidelines and retrieved all accessible studies from the Embase, PubMed, and Web of Science databases up to December 2022. Only studies in which both [18F]FDG PET/MRI and [18F]FDG PET/CT were conducted on each individual patient were included. Two researchers independently extracted data on study characteristics and assessed the methodological quality using the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool.
Results
A total of 539 patients in eight studies were included in this analysis. For T staging, the pooled sensitivity of [18F]FDG PET/CT was 0.90 (95% confidence interval [CI]: 0.81–0.96) and specificity of 0.97 (95% CI: 0.89–1.00), with corresponding values for [18F]FDG PET/MRI of 0.88 (95% CI: 0.78–0.94) and 0.95 (95% CI: 0.87–0.99), respectively. For N staging, the pooled sensitivity of [18F] FDG PET/CT was 0.70 (95% CI: 0.63–0.76), the specificity of 0.92 (95% CI: 0.88–0.95), and the area under the curve (AUC) was 0.90 (standard error [SE] = 0.06). The corresponding values for [18F]FDG PET/MRI were 0.71 (95% CI: 0.65–0.77), 0.91 (95% CI: 0.87–0.94) and 0.88 (SE = 0.06), respectively. For M staging, the pooled sensitivity was 0.79 (95% CI: 0.62–0.91), the specificity was 0.94 (95% CI: 0.90–0.97), and AUC was 0.96 (SE = 0.03) for [18F]FDG PET/CT. The corresponding values were 0.82 (95% CI: 0.70–0.91), 0.96 (95% CI: 0.93–0.98), and 0.94 (SE = 0.03), respectively, for [18F]FDG PET/MRI.
Conclusions
According to the pooled data, [18F]FDG PET/CT performed slightly better in terms of T staging than [18F]FDG PET/MRI. In contrast, with regard to N staging and M staging the staging accuracy of both imaging techniques was comparable. To ensure that results are reliable, more high-level investigations will be required to assess these imaging modalities, in addition to optimized PET/MRI procedures.
Similar content being viewed by others
Data availability
The study’s original contributions are described in the paper. If you have more questions, you can contact the writers.
Abbreviations
- [18F]FDG PET/CT:
-
18F-Fluorodeoxyglucose positron emission tomography/computed tomography
- [18F]FDG PET/MRI:
-
18F-Fluorodeoxyglucose positron emission tomography/magnetic resonance imaging
- NSCLC:
-
Non–small cell lung cancer
- PRISMA-DTA:
-
Preferred Reporting Items for Systematic Reviews and Meta-Analyses for Diagnostic Test Accuracy
- QUADAS-2:
-
Quality Assessment of Diagnostic Accuracy Studies-2
- AUC:
-
Area Under Curve
- SE:
-
Standard error
- Src:
-
Spearman rank correlation coefficient
- TN:
-
True positive
- FP:
-
False positive
- FN:
-
False negative
- TN:
-
True negative
References
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer J Clin 68(6):394–424. https://doi.org/10.3322/caac.21492
Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA (2008) Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 83(5):584–594. https://doi.org/10.4065/83.5.584
National Comprehensive Cancer Network. (2021). NCCN clinical practice guidelines in oncology: Non-small cell lung cancer, Version 3.2021. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf.
Wang M-l, Zhang H, Yu H-j, Tan H, Hu L-z, Kong H-j et al (2023) An initial study on the comparison of diagnostic performance of 18F-FDG PET/MR and 18F-FDG PET/CT for thoracic staging of non-small cell lung cancer: Focus on pleural invasion. Revista Española de Medicina Nuclear e Imagen Molecular (English Edition). 42(1):16–23. https://doi.org/10.1016/j.remnie.2021.12.007
Biederer J, Beer M, Hirsch W, Wild J, Fabel M, Puderbach M et al (2012) MRI of the lung (2/3). Why… when… how? Insights imaging 3(4):355–371. https://doi.org/10.1007/s13244-011-0146-8
Puderbach M, Hintze C, Ley S, Eichinger M, Kauczor HU, Biederer J (2007) MR imaging of the chest: a practical approach at 15T. Eur J Radiol 64(3):345–355. https://doi.org/10.1016/j.ejrad.2007.08.009
Wild J, Marshall H, Bock M, Schad L, Jakob P, Puderbach M (2012) MRI of the lung (1/3): methods. Insights Imaging 3(4):345–353. https://doi.org/10.1007/s13244-012-0176-x
Cerfolio RJ, Ojha B, Bryant AS, Raghuveer V, Mountz JM, Bartolucci AA (2004) The accuracy of integrated PET-CT compared with dedicated PET alone for the staging of patients with nonsmall cell lung cancer. Ann Thorac Surg 78(3):1017–1023. https://doi.org/10.1016/j.athoracsur.2004.02.067
De Wever W, Ceyssens S, Mortelmans L, Stroobants S, Marchal G, Bogaert J et al (2007) Additional value of PET-CT in the staging of lung cancer: comparison with CT alone, PET alone and visual correlation of PET and CT. Eur Radiol 17:23–32. https://doi.org/10.1007/s00330-006-0284-4
Lardinois D, Weder W, Hany TF, Kamel EM, Korom S, Seifert B et al (2003) Staging of non–small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 348(25):2500–2507. https://doi.org/10.1056/NEJMoa022136
Shim SS, Lee KS, Kim B-T, Chung MJ, Lee EJ, Han J et al (2005) Non–small cell lung cancer: prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging. Radiology 236(3):1011–1019. https://doi.org/10.1148/radiol.2363041310
Antoch G, Stattaus J, Nemat AT, Marnitz S, Beyer T, Kuehl H et al (2003) Non–small cell lung cancer: dual-modality PET/CT in preoperative staging. Radiology 229(2):526–533. https://doi.org/10.1148/radiol.2292021598
Steinert HC (2011) PET and PET-CT of lung cancer. Positron emission tomography. 2011:33-51. https://doi.org/10.1007/978-1-61779-062-1_3
Dahlsgaard-Wallenius SE, Hildebrandt MG, Johansen A, Vilstrup MH, Petersen H, Gerke O et al (2021) Hybrid PET/MRI in non-small cell lung cancer (NSCLC) and lung nodules—a literature review. Eur J Nucl Med Mol Imaging 48:584–591. https://doi.org/10.1007/s00259-020-04955-z
Ohno Y, Takeshi Y, Takenaka D, Koyama H, Aoyagi K, Yui M (2020) Comparison of diagnostic accuracy for TNM stage among whole-body MRI and coregistered PET/MRI using 1.5-T and 3-T MRI systems and integrated PET/CT for non-small cell lung cancer. Am J Roentgenol 215(5):1191–1198. https://doi.org/10.2214/AJR.19.22565
Ohno Y, Koyama H, Yoshikawa T, Takenaka D, Seki S, Yui M et al (2015) Three-way comparison of whole-body MR, coregistered whole-body FDG PET/MR, and integrated whole-body FDG PET/CT imaging: TNM and stage assessment capability for non-small cell lung cancer patients. Radiology 275(3):849–861. https://doi.org/10.1148/radiol.14140936
Lee SM, Goo JM, Park CM, Yoon SH, Paeng JC, Cheon GJ et al (2016) Preoperative staging of non-small cell lung cancer: prospective comparison of PET/MR and PET/CT. Eur Radiol 26(11):3850–3857. https://doi.org/10.1007/s00330-016-4255-0
Kirchner J, Sawicki LM, Nensa F, Schaarschmidt BM, Reis H, Ingenwerth M et al (2019) Prospective comparison of F-18-FDG PET/MRI and F-18-FDG PET/CT for thoracic staging of non-small cell lung cancer. Eur J Nucl Med Mol Imaging 46(2):437–445. https://doi.org/10.1007/s00259-018-4109-x
Huellner MW, Galiza Barbosa FD, Husmann L, Pietsch CM, Mader CE, Burger IA et al (2016) TNM staging of non-small cell lung cancer: comparison of PET/MR and PET/CT. J Nucl Med 57(1):21–26. https://doi.org/10.2967/jnumed.115.162040
Heusch P, Buchbender C, Köhler J, Nensa F, Gauler T, Gomez B et al (2014) Thoracic staging in lung cancer: prospective comparison of 18F-FDG PET/MR imaging and 18F-FDG PET/CT. J Nucl Med 55(3):373–378. https://doi.org/10.2967/jnumed.113.129825
Fraioli F, Screaton NJ, Janes SM, Win T, Menezes L, Kayani I et al (2015) Non-small-cell lung cancer resectability: diagnostic value of PET/MR. Eur J Nucl Med Mol Imaging 42(1):49–55. https://doi.org/10.1007/s00259-014-2873-9
Pieterman RM, van Putten JW, Meuzelaar JJ, Mooyaart EL, Vaalburg W, Koëter GH et al (2000) Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med 343(4):254–261. https://doi.org/10.1056/NEJM200007273430404
van Tinteren H, Hoekstra OS, Smit EF, van den Bergh JH, Schreurs AJ, Stallaert RA et al (2002) Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet 359(9315):1388–1393. https://doi.org/10.1016/s0140-6736(02)08352-6
Bunyaviroch T, Coleman RE (2006) PET evaluation of lung cancer. J Nucl Med 47(3):451–469
Liam CK, Andarini S, Lee P, Ho JC, Chau NQ, Tscheikuna J (2015) Lung cancer staging now and in the future. Respirology 20(4):526–534. https://doi.org/10.1111/resp.12489
Bruzzi JF, Munden RF (2006) PET/CT imaging of lung cancer. J Thorac Imaging 21(2):123–136. https://doi.org/10.1097/00005382-200605000-00004
Catalano OA, Rosen BR, Sahani DV, Hahn PF, Guimaraes AR, Vangel MG et al (2013) Clinical impact of PET/MR imaging in patients with cancer undergoing same-day PET/CT: initial experience in 134 patients—a hypothesis-generating exploratory study. Radiology 269(3):857–869. https://doi.org/10.1148/radiol.13131306
Mirshahvalad SA, Metser U, Basso Dias A, Ortega C, Yeung J, Veit-Haibach P (2023) (18)F-FDG PET/MRI in detection of pulmonary malignancies: a systematic review and meta-analysis. Radiology 307(2):e221598. https://doi.org/10.1148/radiol.221598
Shahraki Mojahed B, Saravani K, Parooie F (2022) Thoracic staging in patients with non-small cell lung cancer: a systematic review and meta-analysis on diagnostic accuracy of [18F]FDG PET/MRI and [18F]FDG PET/CT. Nucl Med Rev Cent East Eur. https://doi.org/10.5603/NMR.a2022.0037
Sawicki LM, Grueneisen J, Buchbender C, Schaarschmidt BM, Gomez B, Ruhlmann V et al (2016) Comparative performance of 18F-FDG PET/MRI and 18F-FDG PET/CT in detection and characterization of pulmonary lesions in 121 oncologic patients. J Nucl Med 57(4):582–586. https://doi.org/10.2967/jnumed.115.167486
Sawicki LM, Grueneisen J, Buchbender C, Schaarschmidt BM, Gomez B, Ruhlmann V et al (2016) Evaluation of the outcome of lung nodules missed on 18F-FDG PET/MRI compared with 18F-FDG PET/CT in patients with known malignancies. J Nucl Med 57(1):15–20. https://doi.org/10.2967/jnumed.115.162966
Raad RA, Friedman KP, Heacock L, Ponzo F, Melsaether A, Chandarana H (2016) Outcome of small lung nodules missed on hybrid PET/MRI in patients with primary malignancy. J Magn Reson Imaging 43(2):504–511. https://doi.org/10.1002/jmri.25005
Rauscher I, Eiber M, Fürst S, Souvatzoglou M, Nekolla SG, Ziegler SI et al (2014) PET/MR imaging in the detection and characterization of pulmonary lesions: technical and diagnostic evaluation in comparison to PET/CT. J Nucl Med 55(5):724–729. https://doi.org/10.2967/jnumed.113.129247
Chandarana H, Heacock L, Rakheja R, DeMello LR, Bonavita J, Block TK et al (2013) Pulmonary nodules in patients with primary malignancy: comparison of hybrid PET/MR and PET/CT imaging. Radiology 268(3):874–881. https://doi.org/10.1148/radiol.13130620
Machado Medeiros T, Altmayer S, Watte G, Zanon M, Basso Dias A, Henz Concatto N et al (2020) 18F-FDG PET/CT and whole-body MRI diagnostic performance in M staging for non-small cell lung cancer: a systematic review and meta-analysis. Eur Radiol 30(7):3641–3649. https://doi.org/10.1007/s00330-020-06703-1
Author information
Authors and Affiliations
Contributions
ZL and DS designed and AL proofed the work. Data was gathered and analyzed by DS and AL. The text was by ZL. The article was written by all authors and accepted.
Corresponding author
Ethics declarations
Conflict of interest
The authors state that the study had no business or pecuniary conflicts of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Li, Z., Sun, D., Li, A. et al. Head-to-head comparison of [18F]FDG PET/MRI and [18F] FDG PET/CT for TNM staging in non-small cell lung cancer: a systematic review and meta-analysis. Clin Transl Imaging (2024). https://doi.org/10.1007/s40336-024-00622-7
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s40336-024-00622-7